Environmental release of oseltamivir from a Norwegian sewage treatment plant during the 2009 influenza A (H1N1) pandemic

Science of the Total Environment

Volumn 414, Issue , 2012, Pages 632-638

  Leknes, Henriette ^a   Sturtzel, Iren Elisabeth ^a   Dye, Christian ^a  

^a NORWEGIAN INSTITUTE FOR AIR RESEARCH   (Norway)

Author keywords

H1N1; Oseltamivir; Pandemic; Tamiflu; UPLC TOF; Wastewater treatment

Indexed keywords

H1N1; OSELTAMIVIR; PANDEMIC; TAMIFLU; UPLC-TOF;

CARBOXYLATION; EFFLUENT TREATMENT; EFFLUENTS; WASTEWATER; WASTEWATER TREATMENT;

SEWAGE TREATMENT PLANTS;

CARBOXYLIC ACID; OSELTAMIVIR;

ANALYTICAL METHOD; CONCENTRATION (COMPOSITION); DATA SET; DRUG PRESCRIBING; EFFLUENT; EPIDEMIC; INFLUENZA; SEWAGE TREATMENT; STATISTICAL ANALYSIS; WASTEWATER; WATER TREATMENT;

2009 H1N1 INFLUENZA; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; ELECTROSPRAY; ENVIRONMENTAL RELEASE; ETHNIC GROUP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NORWAY; NORWEGIAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEWAGE EFFLUENT; SEWAGE TREATMENT PLANT; SOLID PHASE EXTRACTION; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WASTE WATER MANAGEMENT;

CHROMATOGRAPHY, LIQUID; ENVIRONMENTAL MONITORING; EPIDEMIOLOGICAL MONITORING; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MOLECULAR STRUCTURE; NORWAY; OSELTAMIVIR; PANDEMICS; SEWAGE; WASTE DISPOSAL, FLUID; WATER POLLUTANTS, CHEMICAL;

NORWAY; OSLO [NORWAY];

EID: 84855545033     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2011.11.004     Document Type: Article

References (34)

1. Accinelli C., Caracciolo A.B., Grenni P. Degradation of the antiviral drug oseltamivir carboxylate in surface water samples. Int J Environ Anal Chem 2007, 87:579-587.
2. Accinelli C., Sacca M.L., Batisson I., Fick J., Mencarelli M., Grabic R. Removal of oseltamivir (Tamiflu) and other selected pharmaceuticals from wastewater using a granular bioplastic formulation entrapping propagules of Phanerochaete chrysosporium. Chemosphere 2010, 81:436-443.
3. Accinelli C., Sacca M.L., Fick J., Mencarelli M., Lindberg R., Olsen B. Dissipation and removal of oseltamivir (Tamiflu) in different aquatic environments. Chemosphere 2010, 79:891-897.
4. Bahrami G., Mohammadi B., Kiani A. Determination of oseltamivir carboxylic acid in human serum by solid phase extraction and high performance liquid chromatography with UV detection. J Chromatogr B 2008, 864:38-42.
5. Bartels P., von Tumpling W. The environmental fate of the antiviral drug oseltamivir carboxylate in different waters. Sci Total Environ 2008, 405:215-225.
6. Breivik K., Bjerkeng B., Wania F., Magnusson J., Helland A., Pacyna J.M. The Oslofjord POP Model v.1.0. A fugacity-based non-steady state non-equilibrium multimedia fate and transport model NILU OR 24/2003. Available at. http://www.nilu.no/data/inc/leverfil.cfm?id=5252&type=6.
7. Breivik K., Bjerkeng B., Wania F., Helland A., Magnusson J. Modeling the fate of polychlorinated biphenyls in the inner Oslofjord, Norway. Environ Toxicol Chem 2004, 23:2386-2395.
8. Caracciolo A.B., Grenni P., Sacca M.L. Effect of the antiviral drug oseltamivir (Tamiflu) on the bacterial community structure of a surface water ecosystem analyzed using fluorescence in situ hybridization. Bull Environ Contam Toxicol 2010, 85:443-446.
9. Eisenberg E.J., Cundy K.C. High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde. J Chromatogr B 1998, 716:267-273.
10. Ellis J.B. Antiviral pandemic risk assessment for urban receiving waters. Water Sci Technol 2010, 61:879-884.
11. Fick J., Lindberg R.H., Tysklind M., Haemig P.D., Waldenstrom J., Wallensten A., et al. Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. PLoS One 2007, 2.
12. Ghosh G.C., Nakada N., Yamashita N., Tanaka H. Occurrence and fate of oseltamivir carboxylate (Tamiflu) and amantadine in sewage treatment plants. Chemosphere 2010, 81:13-17.
13. Ghosh G.C., Nakada N., Yamashita N., Tanaka H. Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. Environ Health Perspect 2010, 118:103-107.
14. Goncalves C., Perez S., Osorio V., Petrovic M., Alpendurada M.F., Barcelo D. Photofate of oseltamivir (Tamiflu) and oseltamivir carboxylate under natural and simulated solar irradiation: kinetics, identification of the transformation products, and environmental occurrence. Environ Sci Technol 2011, 45:4307-4314.
15. He G., Massarella J., Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999, 37:471-484.
16. Hoffman-La Roche Limited Product Monograph Tamiflu Part II: Scientific information Available at. http://www.rochecanada.com/fmfiles/re7234008/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Tamiflu/tamifluSIE.pdf.
17. Hutchinson T.H., Beesley A., Frickers P.E., Readman J.W., Shaw J.P., Straub J.O. Extending the environmental risk assessment for oseltamivir (Tamiflu (R)) under pandemic use conditions to the coastal marine compartment. Environ Int 2009, 35:931-936.
18. Lindegardh N., Hanpithakpong W., Wattanagoon Y., Singhasivanon P., White N.J., Day N.P.J. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. J Chromatogr B 2007, 859:74-83.
19. Massarella J.W., He G.Z., Dorr A., Nieforth K., Ward P., Brown A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 2000, 40:836-843.
20. NIPH-Norwegian Institute of Public Health Influenza surveillance 2009-10, week 51 (Norwegian only) Available at, Accessed 01.02.2011. http://www.fhi.no/artikler/?id=81897.
21. NIPH-Norwegian Institute of Public Health The Norwegian Prescription Database (NorPD) Available at, Accessed 07.02.2011. http://www.norpd.no/.
22. Prasse C., Schlusener M.P., Schulz R., Ternes T.A. Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance?. Environ Sci Technol 2010, 44:1728-1735.
23. Rønning M., Sakshaug S., Strøm H., Berg C.L., Litleskare I., Blix H.S., et al. Drug Consumption in Norway 2005-2009 2010, Norwegian Institute of Public Health, Available at. http://www.fhi.no/dokumenter/51b02c12c3.pdf.
24. Sagberg P., Ryrfors P., Berg K.G. 10 years of operation of an integrated nutrient removal treatment plant: ups and downs. Background and water treatment. Water Sci Technol 2006, 53:83-90.
25. Singer A.C., Nunn M.A., Gould E.A., Johnson A.C. Potential risks associated with the proposed widespread use of Tamiflu. Environ Health Perspect 2007, 115:102-106.
26. Singer A.C., Howard B.M., Johnson A.C., Knowles C.J., Jackman S., Accinelli C., et al. Meeting report: risk assessment of tamiflu use under pandemic conditions. Environ Health Perspect 2008, 116:1563-1567.
27. Singer A.C., Johnson A.C., Anderson P.D., Snyder S.A. Reassessing the risks of Tamiflu use during a pandemic to the Lower Colorado River. Environ Health Perspect 2008, 116:A285-A286.
28. Slater F.R., Singer A.C., Turner S., Barr J.J., Bond P.L. Pandemic pharmaceutical dosing effects on wastewater treatment: no adaptation of activated sludge bacteria to degrade the antiviral drug Oseltamivir (Tamiflu (R)) and loss of nutrient removal performance. FEMS Microbiol Lett 2011, 315:17-22.
29. Soderstrom H., Jarhult J.D., Olsen B., Lindberg R.H., Tanaka H., Fick J. Detection of the antiviral drug oseltamivir in aquatic environments. PLoS One 2009, 4.
30. Straub J.O. An environmental risk assessment for oseltamivir (Tamiflu (R)) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions. Ecotoxicol Environ Saf 2009, 72:1625-1634.
31. Thomas K.V., Dye C., Schlabach M., Langford K.H. Source to sink tracking of selected human pharmaceuticals from two Oslo city hospitals and a wastewater treatment works. J Environ Monit 2007, 9:1410-1418.
32. Vasskog T., Anderssen T., Pedersen-Bjergaard S., Kallenborn R., Jensen E. Occurrence of selective serotonin reuptake inhibitors in sewage and receiving waters at Spitsbergen and in Norway. J Chromatogr A 2008, 1185:194-205.
33. Wiltshire H., Wiltshire B., Citron A., Clarke T., Serpe C., Gray D., et al. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B 2000, 745:373-388.
34. World Health Organization (WHO) WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics Available at, Accessed 10.02.2011. http://www.who.int/csr/resources/publications/influenza/11_29_01_A.pdf.